US Patent
US7598276 — Pharmaceutical salts and polymorphs of a factor Xa inhibitor
Composition of Matter · Assigned to Millennium Pharmaceuticals Inc · Expires 2026-11-08 · 0y remaining
Vulnerability score
22/100
Ironclad — strong claim type, well-established, deep family
What this patent protects
This patent protects salts of a compound that inhibits mammalian factor Xa, along with methods of making that compound.
USPTO Abstract
The present invention provides for salts comprising a compound of Formula I and an acid that has activity against mammalian factor Xa. The present invention is also directed to methods of making the compound of Formula I.
Drugs covered by this patent
- Bevyxxa (BETRIXABAN) · Portola Pharms Inc
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.